Resistance of novel mouse strains different in MHC class I and the NKC domain to the development of experimental tumors

Fišerová,Anna; Richter,Jan; Čapková,Katarína; Bieblová,Jana; Mikyšková,Romana; Reiniš,Milan; Indrová,Marie

doi:10.3892/ijo.2016.3561

Resistance of novel mouse strains different in MHC class I and the NKC domain to the development of experimental tumors

Authors:
- Anna Fišerová
- Jan Richter
- Katarína Čapková
- Jana Bieblová
- Romana Mikyšková
- Milan Reiniš
- Marie Indrová
View Affiliations

Affiliations: Department of Health Care Disciplines and Population Protection, Czech Technical University in Prague, Faculty of Biomedical Engineering, Sportovců 2311, 27201 Kladno, Czech Republic, Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the AS CR, v.v.i., Prague, Czech Centre for Phenogenomics, Division BIOCEV, Průmyslová 595, 252 42 Vestec, Czech Republic
Published online on: June 3, 2016 https://doi.org/10.3892/ijo.2016.3561
Pages: 763-772

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To elucidate the immunological mechanisms critical for tumor progression, we bred novel mouse strains, different in the NKC and H-2D domains. We used inbreeding to generate hybrids of Balb/c and C57BL/6 of stable H-2Db+d-NK1.1neg and H-2Db-d+NK1.1high phenotypes. We analyzed the growth of three established MHC class I-deficient tumor cell lines: TC-1/A9 tumor (HPV-associated) and B16F10 melanoma, both syngeneic to C57BL/6, and the MCB8 (3-methycholanthrene-induced tumor) syngeneic to Balb/c. Furthermore, we induced colorectal carcinoma by azoxymethane-DSS treatment to test the susceptibility to chemically-induced primary cancer. We found that the novel strains spontaneously regressed the tumor transplants syngeneic to both Balb/c (MCB8) and C57BL/6 (B16F10 and TC-1/A9) mice. The H2-Db+d-NK1.1neg, but not the H2-Db-d+NK1.1high strain was also highly resistant to chemically-induced colorectal cancer in comparison to the parental mice. The immune changes during TC-1/A9 cancer development involved an increase of the NK cell distribution in the peripheral blood and spleen along with higher expression of NKG2D activation antigen; this was in correlation with the time-dependent rise of cytotoxic activity in comparison to C57BL/6 mice. The TC-1/A9 cancer regression was accompanied by higher proportion of B cells in the spleen and B220+/CD86+ activated antigen-presenting B cells distributed in the lymphoid organs, as well as in the periphery. The changes in the T-cell population were represented mainly by the prevalence of T helper cells reflected by grown CD4/CD8 ratio, most prominent in the b+d-NK1.1neg strain. The results of the present study imply usefulness of the two novel mouse strains as an experimental model for further studies of tumor resistance mechanisms.

View Figures

View References

1	Lu H, Ouyang W and Huang C: Inflammation, a key event in cancer development. Mol Cancer Res. 4:221–233. 2006. View Article : Google Scholar : PubMed/NCBI
2	Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI
3	Macaluso M, Paggi MG and Giordano A: Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene. 22:6472–6478. 2003. View Article : Google Scholar : PubMed/NCBI
4	Swann JB and Smyth MJ: Immune surveillance of tumors. J Clin Invest. 117:1137–1146. 2007. View Article : Google Scholar : PubMed/NCBI
5	Ghiringhelli F, Apetoh L, Housseau F, Kroemer G and Zitvogel L: Links between innate and cognate tumor immunity. Curr Opin Immunol. 19:224–231. 2007. View Article : Google Scholar : PubMed/NCBI
6	Xu D, Gu P, Pan PY, Li Q, Sato AI and Chen SH: NK and CD8⁺ T cell-mediated eradication of poorly immunogenic B16–F10 melanoma by the combined action of IL-12 gene therapy and 4–1BB costimulation. Int J Cancer. 109:499–506. 2004. View Article : Google Scholar : PubMed/NCBI
7	Higuchi DA, Cahan P, Gao J, Ferris ST, Poursine-Laurent J, Graubert TA and Yokoyama WM: Structural variation of the mouse natural killer gene complex. Genes Immun. 11:637–648. 2010. View Article : Google Scholar : PubMed/NCBI
8	Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ and Schreiber RD: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:1107–1111. 2001. View Article : Google Scholar : PubMed/NCBI
9	Yokoyama WM, Ryan JC, Hunter JJ, Smith HR, Stark M and Seaman WE: cDNA cloning of mouse NKR-P1 and genetic linkage with LY-49. Identification of a natural killer cell gene complex on mouse chromosome 6. J Immunol. 147:3229–3236. 1991.PubMed/NCBI
10	Yokoyama WM and Seaman WE: The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: The NK gene complex. Annu Rev Immunol. 11:613–635. 1993. View Article : Google Scholar : PubMed/NCBI
11	Hao L, Klein J and Nei M: Heterogeneous but conserved natural killer receptor gene complexes in four major orders of mammals. Proc Natl Acad Sci USA. 103:3192–3197. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kane KP, Lavender KJ and Ma BJ: Ly-49 receptors and their functions. Crit Rev Immunol. 24:321–348. 2004. View Article : Google Scholar
13	Carlyle JR, Mesci A, Ljutic B, Belanger S, Tai LH, Rousselle E, Troke AD, Proteau MF and Makrigiannis AP: Molecular and genetic basis for strain-dependent NK1.1 alloreactivity of mouse NK cells. J Immunol. 176:7511–7524. 2006. View Article : Google Scholar : PubMed/NCBI
14	Carlyle JR, Mesci A, Fine JH, Chen P, Bélanger S, Tai LH and Makrigiannis AP: Evolution of the Ly49 and Nkrp1 recognition systems. Semin Immunol. 20:321–330. 2008. View Article : Google Scholar : PubMed/NCBI
15	Plougastel B, Dubbelde C and Yokoyama WM: Cloning of Clr, a new family of lectin-like genes localized between mouse Nkrp1a and Cd69. Immunogenetics. 53:209–214. 2001. View Article : Google Scholar : PubMed/NCBI
16	Rahim MM, Chen P, Mottashed AN, Mahmoud AB, Thomas MJ, Zhu Q, Brooks CG, Kartsogiannis V, Gillespie MT, Carlyle JR, et al: The mouse NKR-P1B:Clr-b recognition system is a negative regulator of innate immune responses. Blood. 125:2217–2227. 2015. View Article : Google Scholar : PubMed/NCBI
17	Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O and Matzinger P: CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood. 109:5346–5354. 2007. View Article : Google Scholar : PubMed/NCBI
18	Taieb J, Chaput N, Ménard C, Apetoh L, Ullrich E, Bonmort M, Péquignot M, Casares N, Terme M, Flament C, et al: A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med. 12:214–219. 2006. View Article : Google Scholar : PubMed/NCBI
19	Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M, Brockstedt D, Dubensky TW, Stins MF, Lanier LL, et al: Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med. 12:207–213. 2006. View Article : Google Scholar : PubMed/NCBI
20	Maroof A, Beattie L, Zubairi S, Svensson M, Stager S and Kaye PM: Posttranscriptional regulation of II10 gene expression allows natural killer cells to express immunoregulatory function. Immunity. 29:295–305. 2008. View Article : Google Scholar : PubMed/NCBI
21	Huarte E, Rynda-Apple A, Riccardi C, Skyberg JA, Golden S, Rollins MF, Ramstead AG, Jackiw LO, Maddaloni M and Pascual DW: Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE. J Autoimmun. 37:328–341. 2011. View Article : Google Scholar : PubMed/NCBI
22	Perona-Wright G, Mohrs K, Szaba FM, Kummer LW, Madan R, Karp CL, Johnson LL, Smiley ST and Mohrs M: Systemic but not local infections elicit immunosuppressive IL-10 production by natural killer cells. Cell Host Microbe. 6:503–512. 2009. View Article : Google Scholar : PubMed/NCBI
23	Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB and Oldstone MB: Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. 12:1301–1309. 2006. View Article : Google Scholar : PubMed/NCBI
24	Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, Ghiringhelli F, Viaud S, Ryffel B, Yagita H, et al: Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res. 72:2757–2767. 2012. View Article : Google Scholar : PubMed/NCBI
25	Cook KD and Whitmire JK: The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection. J Immunol. 190:641–649. 2013. View Article : Google Scholar
26	Noval Rivas M, Hazzan M, Weatherly K, Gaudray F, Salmon I and Braun MY: NK cell regulation of CD4 T cell-mediated graft-versus-host disease. J Immunol. 184:6790–6798. 2010. View Article : Google Scholar : PubMed/NCBI
27	Smahel M, Síma P, Ludvíková V, Marinov I, Pokorná D and Vonka V: Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine. 21:1125–1136. 2003. View Article : Google Scholar : PubMed/NCBI
28	Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM and Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:21–26. 1996.PubMed/NCBI
29	Neufert C, Becker C and Neurath MF: An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc. 2:1998–2004. 2007. View Article : Google Scholar : PubMed/NCBI
30	Richter J, Capková K, Hříbalová V, Vannucci L, Danyi I, Malý M and Fišerová A: Collagen-induced arthritis: Severity and immune response attenuation using multivalent N-acetyl glucosamine. Clin Exp Immunol. 177:121–133. 2014. View Article : Google Scholar : PubMed/NCBI
31	Scalzo AA, Lyons PA, Fitzgerald NA, Forbes CA and Shellam GR: The BALB. B6-Cmv1r mouse: A strain congenic for Cmv1 and the NK gene complex. Immunogenetics. 41:148–151. 1995. View Article : Google Scholar
32	Taherzadeh Z, VanBavel E, de Vos J, Matlung HL, van Montfrans G, Brewster LM, Seghers L, Quax PH and Bakker EN: Strain-dependent susceptibility for hypertension in mice resides in the natural killer gene complex. Am J Physiol Heart Circ Physiol. 298:H1273–H1282. 2010. View Article : Google Scholar : PubMed/NCBI
33	Brown MG, Scalzo AA, Stone LR, Clark PY, Du Y, Palanca B and Yokoyama WM: Natural killer gene complex (Nkc) allelic variability in inbred mice: Evidence for Nkc haplotypes. Immunogenetics. 53:584–591. 2001. View Article : Google Scholar : PubMed/NCBI
34	Radulovic K, Manta C, Rossini V, Holzmann K, Kestler HA, Wegenka UM, Nakayama T and Niess JH: CD69 regulates type I IFN-induced tolerogenic signals to mucosal CD4 T cells that attenuate their colitogenic potential. J Immunol. 188:2001–2013. 2012. View Article : Google Scholar : PubMed/NCBI
35	Ljunggren HG: Cancer immunosurveillance: NKG2D breaks cover. Immunity. 28:492–494. 2008. View Article : Google Scholar : PubMed/NCBI
36	Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL and Phillips JH: An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 285:730–732. 1999. View Article : Google Scholar : PubMed/NCBI
37	Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 3:781–790. 2003. View Article : Google Scholar : PubMed/NCBI
38	Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips JH and Lanier LL: Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity. 12:721–727. 2000. View Article : Google Scholar : PubMed/NCBI
39	Diefenbach A, Jamieson AM, Liu SD, Shastri N and Raulet DH: Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 1:119–126. 2000. View Article : Google Scholar
40	Diefenbach A, Jensen ER, Jamieson AM and Raulet DH: Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 413:165–171. 2001. View Article : Google Scholar : PubMed/NCBI
41	Végran F, Apetoh L and Ghiringhelli F: Th9 cells: A novel CD4 T-cell subset in the immune war against cancer. Cancer Res. 75:475–479. 2015. View Article : Google Scholar : PubMed/NCBI
42	Reinis M, Símová J, Indrová M, Bieblová J, Pribylová H, Moravcová S, Jandlová T and Bubeník J: Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours. Int J Oncol. 30:1011–1017. 2007.PubMed/NCBI
43	Indrová M, Símová J, Bieblová J, Bubeník J and Reinis M: NK1.1⁺ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours. Oncol Rep. 25:281–288. 2011.
44	Wang D and DuBois RN: Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 36:1085–1093. 2015. View Article : Google Scholar : PubMed/NCBI
45	Mikyšková R, Indrová M, Polláková V, Bieblová J, Símová J and Reiniš M: Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors. J Immunother. 35:374–384. 2012. View Article : Google Scholar
46	Guo Y, Wu Y, Zhao M, Kong XP and Liu Y: Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain. J Exp Med. 181:1345–1355. 1995. View Article : Google Scholar : PubMed/NCBI